A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, and Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics; Including an Open-label Cohort to Determine the Effect of Food on the Pharmacokinetics of D-0120-NA Tablet in Healthy Volunteers in the United States
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
At a glance
- Drugs D-0120 (Primary)
- Indications Gout
- Focus Adverse reactions
- Sponsors InventisBio
- 02 Feb 2018 Planned number of patients changed from 32 to 40.
- 02 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Oct 2017 New trial record